30 closest matches · ranked by relevance
Dementia · Pain · Alzheimer's Disease
Primary: Number of Participants With Aggression as Per the Cohen Mansfield Agitation Inventory, Aggression Subscale — 29; 23 Participants — p=0.29
Pneumonia
Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 38690; 27971 Extended-Spectrum Days-of-Therapy
Hereditary Transthyretin Amyloidosis (ATTRv) · Polyneuropathy
Primary: Change in Neuropathy Impairment Score (NIS) at Month 12 for ATTRv — 1.6 Change in score*months
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Transthyretin Gene Mutations · Transthyretin Amyloidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 621; 175; 66; 4 Participants
Femoral Fracture (Proximal)
Primary: Success in Terms of the Merle D'Aubigne Postel Score for Pain Category — 4.1; 4.4; 4.5; 4.6 Units on a scale
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Primary: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) — -21.345; -8.150 meters — p=0.0162
Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Primary: Change From Baseline in Neuropathy Impairment Score-lower Limb (NIS-LL) Total Score at Week 72 — 2.3 Units on a scale
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
Premedication · Endotracheal Intubation
Primary: Number of Patients With Prolonged Desaturation — 54; 53 Participants — p=0.38
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Chronic Pancreatitis
Primary: Islet Graft Function — 233; 354 ng/ml*min
TTR-mediated Amyloidosis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 1; 3; 2; 7 Participants
Preeclampsia
Primary: Increase in Gestational Age in Days — 5.0; 6.0 days
TTR-mediated Amyloidosis · Amyloidosis, Hereditary · Amyloid Neuropathies, Familial
Primary: Modified Neuropathy Impairment Score +7 (mNIS+7) — -6.03; 27.96 score on a scale — p=<0.0000001
ATTR-CM
Primary: Number of Participants According to Clinical Diagnosis Predicted Using the Machine Learning (ML) Algorithm — 203; 133; 35; 187 Participants
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Primary: Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66 — 0.2964; 25.0557 scores on a scale — p=0.00000001
Healthy Volunteers · hATTR Amyloidosis
Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 3; 1; 3; 7 Participants
Catecholaminergic Polymorphic Ventricular Tachycardia
Primary: Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery) — 46; 0 number of ventricular beats
Lymphoma, Non-Hodgkin's
Primary: Overall Response Rate — 53.8 percentage of participants
Lymphoma, Diffuse Large B-Cell
Primary: Overall Response Rate — 11.1 percentage of participants
Dementia
Primary: The Neuropsychiatric Inventory (NPI). Measures the Frequency and Severity of Behavioral Symptoms in Dementia. — -38.1; 1.0; -12; -9.8 score on a scale — p=.02
Familial Amyloid Polyneuropathy · ATTR-PN
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 — 62.2; 68.8 percentage of participants
Sudden Cardiac Death
Primary: All-Cause Shock — 129; 178 Participants — p=0.005
Transthyretin Amyloidosis
Primary: Median of Uptake of Evuzamitide as Measured by Volume of Interest in Milliliters — 78.7; 253.6; 177.2; 39.6 mL
Symptomatic Transthyretin Amyloid Cardiomyopathy
Primary: Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) — -3.86 meters
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
Type1 Diabetes
Primary: Percent of Time-in-Range (TIR) on NAP Versus UMPC. — 86.08; 87.25 Percent of time between 70-180 mg/dl — p=0.2
Antithrombin Deficiency, Congenital
Primary: Incidence of Thromboembolic Events Acute Deep Venous Thrombosis (DVT) and/or Thromboembolic Events Other Than Acute Deep Vein Thrombosis (DVT). — 1 participants